SOURCE: Ablynx

June 15, 2010 12:35 ET

ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 5th ANNUAL PIPER JAFFRAY EUROPE HEALTHCARE CONFERENCE

GHENT, BELGIUM--(Marketwire - June 15, 2010) -



GHENT, Belgium, 15 June 2010 - Ablynx [Euronext Brussels: ABLX] today announced that it will webcast its corporate presentation at the 5th Annual Piper Jaffray Europe Healthcare Conference on Tuesday, 22 June 2010 at 02.30 pm BST / 03.30 p.m. CET.

The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and Chairman of Ablynx. The presentation will be webcast live and may be accessed on the home page of Ablynx's website at www.ablynx.com. A replay of the webcast will also be available on the Company's website for 30 days, by default.

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

-ends- About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 230 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007 and raised EUR50 million through an SPO in March 2010.

Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. Ablynx now has over 25 programmes in its therapeutic pipeline including four Nanobodies in clinical development. So far, Nanobodies have been successfully generated against more than 190 different protein targets including several complex targets such as chemokines, GPCRs, ion channels and viruses, which are typically very difficult to address with conventional monoclonal antibodies. Efficacy data have been obtained in 28 in vivo models for Nanobodies against a range of different targets.

Ablynx has an extensive patent position in the field of Nanobodies for healthcare applications. It has exclusive and worldwide rights to more than 130 families of granted patents and pending patent applications, including the Hamers patents covering the basic structure, composition, preparation and uses of Nanobodies.





[HUG#1424191]





Complete version of the press release: http://hugin.info/137912/R/1424191/372852.pdf

Contact Information

  • For more information, please contact

    Ablynx:

    Dr. Edwin Moses
    Chairman and CEO
    t: +32 (0)9 262 00 07
    m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
    e: Email Contact

    Eva-Lotta Allan
    Chief Business Officer
    t: +32 (0)9 262 00 75
    m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
    e: Email Contact